Clinical trial • Phase I • Cardiology|Endocrinology
Clinical trial in Obesity|Right heart failure
Phase I trial for Obesity|Right heart failure. None/Not specified-controlled. 112 participants.
Overview
- Trial Therapeutic Area
- Cardiology|Endocrinology
- Trial Disease
- Obesity|Right heart failure
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 21-06-2024
- First CTIS Authorization Date
- 04-09-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Germany.
- Comparator
- None/Not specified
- Target Sample Size
- 112
Eligibility
Recruits 112 Vulnerable population selected (isVulnerablePopulationSelected=true). No further details on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected=true). No further details on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 112
- Recruitment Window Months
- 28
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 112
Germany
- Earliest CTIS Part Ii Submission Date
- 15-08-2024
- Latest Decision Or Authorization Date
- 05-05-2026
- Processing Time Days
- 628
- Number Of Sites
- 1
- Number Of Participants
- 112
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Ulrike Hövelmann
- Contact Person Email
- ulrike.hoevelmann@profil.com
Sponsor
Primary sponsor
- Full Name
- Corteria Pharmaceuticals
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- France
Related trials
Other published trials that may interest you.
- EPROSARTAN MESILATE for Type 2 diabetes
- semaglutide for Diabetic foot ulcer | Type 2 diabetes mellitus
- Semaglutide for Non-ST-elevation myocardial infarction (NSTEMI)|Unstable angina|Diabetes mellitus
- Semaglutide for Type 2 diabetes mellitus|Cardiovascular disease|Overweight|Obesity
- EZETIMIBE; OBICETRAPIB for Type 2 diabetes|Metabolic syndrome|Elevated LDL-cholesterol